HENDERSON MICHAEL THOMAS 4

What Happened Michael Thomas Henderson, CEO of Apogee Therapeutics (APGE), disposed of a total of 95,046 shares in two transactions. On 2026-07-08 he sold 20,000 shares in an open-market/private sale at a weighted average price of $133.63, generating $2,672,600 in proceeds. On 2026-07-10 he made a bona fide gift of 75,046 shares to a donor-advised fund (reported as $0 consideration).

Key Details

• Sale: 2026-07-08 — 20,000 shares; weighted average price $133.63; total proceeds $2,672,600. Footnote: sale executed under a Rule 10b5-1 trading plan adopted 2025-08-13 (F1). Price reported is a weighted average; per F2 the trade prices ranged $133.52–$133.70 across multiple executions.
• Gift: 2026-07-10 — 75,046 shares transferred as a bona fide gift to a donor-advised fund (F3); reported as $0 consideration.
• Shares owned after the transactions: Not disclosed in this Form 4.
• Filing/timeliness: Form 4 filed 2026-07-10; transactions reported on or within the typical two-business-day window.

Context

• The 10b5-1 plan note means the July 8 sale was likely pre-scheduled under an approved trading plan rather than a spontaneous market-timed sale.
• Gifts to donor-advised funds are common for tax/charitable planning and do not necessarily indicate the insider's view of the company’s prospects.
• Sales provide liquidity and are more routine; purchases generally carry stronger signals about insider optimism. This filing is informational and does not by itself indicate future company performance.